NCT05995444已完成1 期
A Phase 1, Single-Dose, Randomized, Placebo- and Positive-Control, Four-Way, Crossover Study for the Evaluation of the Effect of Epetraborole on QT Intervals in Healthy Adult Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 24
- 试验地点
- 1
- 主要终点
- Changes to QTc interval
研究概览
简要总结
A single-center, 4-way crossover study to evaluate the effect of single therapeutic and supratherapeutic oral doses of epetraborole on the heart rate (HR) corrected QT interval (QTc) by assessing concentration-QT (C-QT) relationship using exposure-response modeling.
详细描述
On Day 1 of each period, subjects will receive 1 of 4 treatments: a single therapeutic dose of epetraborole (Treatment A), a single supratherapeutic dose of epetraborole (Treatment B), a single dose of epetraborole-matching placebo (Treatment C), or a single dose of moxifloxacin (Treatment D). Cardiodynamic ECGs and PK blood samples for epetraborole, metabolite M3, and moxifloxacin (as applicable) will be collected predose and for 24 hours postdose in each period.
There will be a washout of at least 10 days between doses.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Basic Science
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Adult, male or female, 18-65 years of age, inclusive, at the screening visit.
- •Subjects must agree to follow protocol-specified contraception guidance
- •Continuous non smoker for at least 3 months prior to the first dosing based on subject self-reporting
- •Body mass index (BMI) 18.0 and 32.0 kg/m2 at the screening visit.
- •Medically healthy with no clinically significant medical history, physical examination, laboratory profiles, and vital signs, as deemed by the Investigator or designee.
- •No clinically significant history or presence of ECG findings as judged by the Investigator or designee at the screening visit and first check-in
排除标准
- •Is mentally or legally incapacitated or has significant emotional problems at the time of the screening visit or expected during the conduct of the study.
- •History or presence of clinically significant medical or psychiatric condition or disease that, in the opinion of the Investigator or designee, might confound the results of the study or poses an additional risk to the subject by their participation in the study.
- •Presence of bacterial infections requiring the use of antibiotic therapy within 3 months prior to the first dosing.
- •History or presence of alcohol or drug abuse within the past 2 years prior to the first dosing.
- •History of regular alcohol consumption exceeding 7 drinks/week for females or 14 drinks/week for males (1 drink = 5 ounces [150 mL] of wine or 12 ounces [360 mL] of beer or 1.5 ounces [45 mL] of hard liquor) within 6 months prior to the first dosing.
- •History or presence of hypersensitivity or idiosyncratic reaction to the study drugs or related compounds (e.g., fluoroquinolones, epetraborole excipients), or allergy to ECG electrode adhesive patches or adhesive dressings/medical tape.
- •History or presence of any of the following, deemed clinically significant by the Investigator or qualified designee:
- •Ventricular pre-excitation syndrome (Wolff Parkinson White syndrome)
- •Arrhythmia or history of arrhythmia requiring medical intervention
- •Risk factors for TdP (e.g., heart failure, cardiomyopathy, family history of Long QT Syndrome, or sudden unexpected cardiac death at a young age)
- •Sick sinus syndrome, second- or third-degree atrioventricular block, myocardial infarction, pulmonary congestion, symptomatic or significant cardiac arrhythmia, prolonged QTcF interval, or conduction abnormalities
- •Is lactating or has a positive pregnancy test at the screening visit or first check-in (females only).
- •Positive urine drug or alcohol results at the screening visit or first check-in.
- •Positive results for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV) at the screening visit.
- •Positive results for coronavirus disease 2019 (COVID-19) at first check-in.
- •Unable to refrain from or anticipates the use of any drugs, including prescription and non-prescription medications, herbal remedies, or vitamin supplements beginning
- •14 days prior to the first dosing.
- •Has been on a diet incompatible with the on-study diet, in the opinion of the Investigator or designee, within the 30 days prior to the first dosing.
- •Donation of blood or blood products or significant blood loss within 56 days prior to the first dosing or plans to donate blood products through the follow-up contact.
- •Participation in another clinical study and received an investigational agent within 30 days or within 5 half-lives (if known), prior to the first dosing, whichever is longer. The 30-day window will be derived from the date of the last blood collection or dosing, whichever is later, in the previous study to Day 1 of Period 1 of the current study.
研究组 & 干预措施
500 mg epetraborole
Experimental
500 mg epetraborole
干预措施: Epetraborole (Drug)
2000 mg epetraborole
Experimental
2000 mg epetraborole
干预措施: Epetraborole (Drug)
Epetraborole-matching placebo
Placebo Comparator
Epetraborole-matching placebo
干预措施: Epetraborole and matching placebo (Drug)
Epetraborole-matching placebo
Placebo Comparator
Epetraborole-matching placebo
干预措施: Placebo (Drug)
400 mg moxifloxacin
Active Comparator
400 mg moxifloxacin
干预措施: Moxifloxacin (Drug)
结局指标
主要结局
Changes to QTc interval
时间窗: Study Day -1 to Study Day 2
Effect of epetraborole plasma concentrations on the QTc interval using linear mixed effect exposure-response modeling, including the predicted ddQTc at Cmax values corresponding to exposure levels of interest.
次要结局
- Assay sensitivity(Study Day -1 to Study Day 2)
- Orthostatic Vital Signs changes of Heart Rate from supine to standing position.(Study Day 1 through Study Day 14)
- Effect of epetraborole plasma concentrations on other ECG parameters on, PR(Study Day -1 to Study Day 2)
- Effect of epetraborole plasma concentrations on other ECG parameters on QRS duration(Study Day -1 to Study Day 2)
- PK Concentration analysis for epetraborole and metabolite M3 of Cmax(Study Day -1 to Study Day 2)
- Safety Vital Signs changes of blood pressure(Study Day 1 through Study Day 14)
- Effect of epetraborole plasma concentrations on other ECG parameters on QTc(Study Day -1 to Study Day 2)
- Analysis of dQTc(Study Day -1 to Study Day 2)
- PK Concentration analysis for epetraborole and metabolite M3 of AUC0 t(Study Day -1 to Study Day 2)
- Safety Vital Signs changes of body temperature(Study Day 1 through Study Day 14)
- Evaluation of TEAEs(Study Day 1 through Study Day 14)
- Effect of epetraborole plasma concentrations on other ECG parameters on HR.(Study Day -1 to Study Day 2)
- PK Concentration analysis for epetraborole and metabolite M3 of AUC0 inf(Study Day -1 to Study Day 2)
- PK Concentration analysis for epetraborole and metabolite M3 of t½(Study Day -1 to Study Day 2)
- PK Concentration analysis for epetraborole and metabolite M3 of AUC%extrap(Study Day -1 to Study Day 2)
- PK Concentration analysis for epetraborole and metabolite M3 of Tmax(Study Day -1 to Study Day 2)
- PK Concentration analysis for epetraborole and metabolite M3 of Kel(Study Day -1 to Study Day 2)
- PK Concentration analysis for epetraborole and metabolite M3 of CL/F (parent only),(Study Day -1 to Study Day 2)
- PK Concentration analysis for epetraborole and metabolite M3 of Vz/F (parent only)(Study Day -1 to Study Day 2)
- PK Concentration analysis for epetraborole and metabolite M3 of MR Cmax(Study Day -1 to Study Day 2)
- Safety Vital Signs changes of respiratory rate(Study Day 1 through Study Day 14)
- Safety Vital Signs changes of heart rate(Study Day 1 through Study Day 14)
- Orthostatic Vital Signs changes of blood pressure from supine to standing position.(Study Day 1 through Study Day 14)
- PK Concentration analysis for epetraborole and metabolite M3 of MR AUC0 t(Study Day -1 to Study Day 2)
- PK Concentration analysis for epetraborole and metabolite M3 of MR AUC0 inf(Study Day -1 to Study Day 2)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Evaluation of Possible Effects on the QTc Interval of CHF 4226 pMDI in Healthy VolunteersChronic Obstructive Pulmonary DiseaseNCT00777595Chiesi Farmaceutici S.p.A.47
已完成
1 期
E4/DRSP Single and Multiple Dose PK and Early QT StudyContraceptionNCT02874248Estetra55
已完成
1 期
Effect of BIA 5 1058 on Cardiac RepolarizationHeart FailureCardiovascular DiseasePulmonary Arterial HypertensionNCT03489005Bial - Portela C S.A.49
已完成
1 期
Effect of AKB-6548 on Cardiac Repolarization Intervals in Healthy VolunteersHealthy VolunteersNCT02062203Akebia Therapeutics50
已完成
1 期
Effect of Imeglimin on QT/QTc Intervals in Healthy SubjectsQt Interval, Variation inNCT02924337Poxel SA55